MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/mr/roab030

Медицинская библиотека · Modern rheumatology · 2022

Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).

Tanaka Yoshiya, Matsubara Tsukasa, Atsumi Tatsuya, Amano Koichi, Ishiguro Naoki, Sugiyama Eiji, Yamaoka Kunihiro, Combe Bernard G, Kivitz Alan J, Bae Sang-Cheol, Keystone Edward C, Nash Peter, Matzkies Franziska, Bartok Beatrix, Pechonkina Alena, Kondo Akira, Ye Lei, Guo Ying, Tasset Chantal, Sundy John S, Takeuchi Tsutomu

Клиническое исследование III фазыСтатьяПеревод в очереди

Аннотация

OBJECTIVES

Evaluate the efficacy and safety of the Janus kinase-1 inhibitor filgotinib in Japanese patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX).

METHODS

Data from 147 Japanese patients in FINCH 1, a 52-week global Phase 3 study, were analysed up to 24 weeks. Patients received once-daily filgotinib 200 or 100 mg, biweekly adalimumab, or placebo, all with stable background MTX.

RESULTS

In the Japanese population, American College of Rheumatology 20% response rates at Week 12 (primary endpoint) were 77.5%, 65.9%, 53.6%, and 36.8% for filgotinib 200 mg, filgotinib 100 mg, adalimumab, and placebo. Proportions of patients achieving Disease Activity Score with 28 joints <2.6 at Week 24: filgotinib 200 mg, 65.0%; filgotinib 100 mg, 51.2%; adalimumab, 42.9%; and placebo, 5.3%. Incidence rates of serious infections: filgotinib 200 mg, 2.5%; filgotinib 100 mg, 0%; adalimumab, 10.7%; and placebo, 5.3%. Treatment-emergent laboratory abnormalities Grade ≥3 occurred in five (12.5%) filgotinib 200 mg, three (7.3%) filgotinib 100 mg, one (3.6%) adalimumab, and no placebo patients. No deaths were reported among Japanese patients.

CONCLUSIONS

Filgotinib once daily combined with MTX was effective and generally safe and well tolerated up to Week 24 in Japanese patients with RA and inadequate response to MTX.

Для цитирования: Tanaka Yoshiya, Matsubara Tsukasa, Atsumi Tatsuya, Amano Koichi, Ishiguro Naoki, Sugiyama Eiji, Yamaoka Kunihiro, Combe Bernard G, Kivitz Alan J, Bae Sang-Cheol, Keystone Edward C, Nash Peter, Matzkies Franziska, Bartok Beatrix, Pechonkina Alena, Kondo Akira, Ye Lei, Guo Ying, Tasset Chantal, Sundy John S, Takeuchi Tsutomu. Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).. Modern rheumatology. 2022. DOI: 10.1093/mr/roab030.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.